Get started
Author

David Vicente Baz

Observed names: Baz, David Vicente, D. V. Baz, D. Vicente Baz, D.V. Baz, David Baz
Observed institutions: Hospital Universitario Virgen Macarena, Hospital Juan Ramón Jiménez, Hospital Universitario Puerta del Mar, Hospital Universitario Virgen del Rocío, Hospital Clínico Universitario Virgen de la Victoria, Hospital de Palamós, Universidad de Sevilla
ORCID: 0000-0002-6832-9705
Observed ORCID: 0000-0002-6832-9705
OpenAlex ID: A5113235454
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
2018 · Marina Chiara Garassino, Byoung-Chul Cho, et al. · The Lancet Oncology · 590
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
2024 · Myung-Ju Ahn, Kentaro Tanaka, et al. · Journal of Clinical Oncology · 322
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
2024 · James Chih-Hsin Yang, Dae Ho Lee, et al. · Journal of Clinical Oncology · 237
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
2024 · Luis G. Paz-Ares, Oscar Juan-Vidal, et al. · Journal of Clinical Oncology · 167
PDF
LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
2023 · M-J. Ahn, A. Lisberg, et al. · Annals of Oncology · 59
PDF
Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp).
2021 · Xiuning Le, Luis G. Paz-Ares, et al. · Journal of Clinical Oncology · 43
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
2025 · James Chih-Hsin Yang, Mengzhao Wang, et al. · Journal of Clinical Oncology · 35
Immune Microenvironment in Colorectal Cancer: A New Hallmark to Change Old Paradigms
2011 · Luis de la Cruz-Merino, Fernando Henao Carrasco, et al. · Clinical and Developmental Immunology · 28
PDF
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B
2023 · Xiuning Le, Luis G. Paz-Ares, et al. · Cell Reports Medicine · 27
PDF
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study
2023 · Everett E. Vokes, Francoise Mornex, et al. · Journal of Thoracic Oncology · 24
PDF
Irinotecan-Induced Dysarthria
2001 · D. V. Baz, J. S. Bofill, et al. · JNCI Journal of the National Cancer Institute · 23
LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
2022 · S.M. Lee, C. Schulz, et al. · Annals of Oncology · 21
PDF
Tumor Microenvironment and Immune Effects of Antineoplastic Therapy in Lymphoproliferative Syndromes
2010 · Tomás Álvaro, Luis de la Cruz-Merino, et al. · BioMed Research International · 19
PDF
509MO Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
2023 · M-J. Ahn, A.E. Lisberg, et al. · Annals of Oncology · 17
PDF
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
2018 · Edurne Arriola, Ramón García Gómez, et al. · BMC Cancer · 17
PDF
118MO Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): Interim analysis of a phase Ib study
2024 · A. Italiano, B. Besse, et al. · Immuno-Oncology Technology · 15
PDF
974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC)
2022 · S. Novello, D.M. Kowalski, et al. · Annals of Oncology · 15
Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1.
2018 · Luis G. Paz-Ares, Tae Min Kim, et al. · Journal of Clinical Oncology · 15
OA05.04 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study
2023 · B.C. Cho, M.C. Dols, et al. · Journal of Thoracic Oncology · 13
PDF
Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification (METamp) detected by liquid biopsy (LBx).
2022 · Xiuning Le, Luis Paz-Ares, et al. · Journal of Clinical Oncology · 13
Abstract CT051: Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen mRNA vaccine BNT116 + docetaxel in patients with advanced non-small cell lung cancer
2024 · Bala Başak Öven, David Vicente Baz, et al. · Cancer Research · 10
1486 Preliminary results from LuCa-MERIT-1, a phase I trial evaluating BNT116, a fixed antigen mRNA vaccine, plus cemiplimab in advanced non-small cell lung cancer after progression on PD-1 inhibition
2024 · Akin Atmaca, Jürgen Alt, et al. · Journal for ImmunoTherapy of Cancer · 9
Future care for long-term cancer survivors: towards a new model
2021 · M. Provencio, N. Romero, et al. · Clinical & Translational Oncology · 7
PDF
PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC
2017 · L. Paz-Ares, A. Villegas, et al. · Annals of Oncology · 7
PDF
59P Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Nonsquamous (NSQ) histology in the phase III TROPION-Lung01 trial
2024 · N. Girard, I. Okamoto, et al. · ESMO Open · 6
Works count: 55
Citation count: 1,778
H-index: 15
I10-index: 21
Year
Topic
Type